CYTOARM

Next-generation T cell Therapy:
Faster, Safer, and more Affordable

innovative T cell therapy

for various cancers

CytoArm, established in 2020, aims at offering innovative T cell therapy for various cancers. Our team is consisted of inventors of the innovation armed T cell therapy platform, and experts who successfully led the clinical development and commercialization of new drugs, and conducting clinical trials of immune cell therapy.

Safe

Non-viral
Non-genetic modified

Fast

10 Days
from apheresis to reinfusion

more Affordable

for more patients

TECHNOLOGY

BsAb-Armed T technology

We developed the BsAb-Armed T technology, a novel platform of T cell therapy with the shortest and safest manufacture process.

purity over 90%

The cancer-specific BsAb-armed T cells can be generated and expanded with purity over 90%, and then prepared to be reinfused back to the patients in 10 days.

blood cancer, various solid tumors, and malignant metastatic tumors

Preclinical studies have shown that the BsAb-armed T cells are able to effectively treat blood cancer, various solid tumors, and malignant metastatic tumors without severe cellular cytokine release and significant toxicity.

TECHNOLOGY2

Team

Lorem ipsum dolor sit amet, te has solet postea. Voluptua quaestio dissentias has ex, no interpretaris, viderer pertinax repudiandae ne ius, qui ne porro insolens instructior.

Team

Lorem ipsum dolor sit amet, te has solet postea. Voluptua quaestio dissentias has ex, no interpretaris, viderer pertinax repudiandae ne ius, qui ne porro insolens instructior.

Team

Lorem ipsum dolor sit amet, te has solet postea. Voluptua quaestio dissentias has ex, no interpretaris, viderer pertinax repudiandae ne ius, qui ne porro insolens instructior.

Meet Our Team

Lorem ipsum dolor sit amet consectet adipisc elit, sed do eiusm por incididut laboreLorem ipsum dolor sit amet, consectet adipiscing elit.